Better HER2 testing for HER2-low breast cancer on Enhertu
Part of Cancer clinical trials.
This study looks at using a more detailed lab test to measure HER2 levels in people with HER2-low metastatic breast cancer who are starting or have just started treatment with Enhertu. The goal is to see if this test can help doctors better understand who might benefit from Enhertu.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have metastatic breast cancer that is HER2-low (specifically 1+ on a standard lab test).
- You plan to start or have recently started treatment with Enhertu (T-DXd).
- You have a stored tumor sample from a recent biopsy (not from a bone sample that was decalcified).
- You do not have HER2-positive breast cancer (3+ or 2+ with a positive FISH test).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.
This study looks at how well the drug Enhertu works for patients with HER2-low breast cancer that has spread. If you are already planning to start Enhertu, researchers will collect data from your regular care to learn more about its effectiveness.
This trial is testing a drug called Enhertu for men whose prostate cancer has spread and is no longer responding to hormone treatments. You may join if you have a tumor sample that can be tested for a protein called HER2.
This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.
This trial tests a combination of a targeted drug (Enhertu) with precise radiation (SRS) for people whose HER2-positive breast cancer has spread to the brain. It aims to see if this combo is safe and effective for treating brain metastases.
This trial compares two drugs, sacituzumab govitecan (Trodelvy) and trastuzumab deruxtecan (Enhertu), in people with a specific type of advanced breast cancer. It aims to see which drug works better and to understand how the cancer responds to treatment over time.
Hear when a new HER2-positive Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.